Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03176186 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Xenon for Neuroprotection During Post-Cardiac Arrest Syndrome in Comatose Survivors of an Out of Hospital Cardiac Arrest

Study acronym: XePOHCAS
StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv10
  2. Lead sponsor: NeuroproteXeon, Inc. to Invero Pharma, Inc.v9 Show 5 more changesShow less
    • Primary completion date: Oct 15, 2020 to Apr 2029
    • Start date: Dec 20, 2018 to Mar 2026
    • Trial status: Recruiting to Not Yet Recruiting
    • Study completion date: Dec 15, 2020 to May 2030
    • Site details revised at 10 of 10 sites
  3. Site details revised at 2 of 10 sitesv8
  4. Study sites: 8 to 10v7
  5. Study sites: 7 to 8v6
Show 4 earlier versionsHide 4 earlier versions
  1. Trial status: Active, Not Recruiting to Recruiting
    • Primary completion date: Jul 15, 2020 to Oct 15, 2020
    • Site details revised at 7 of 7 sites
    v5
  2. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 7 of 7 sites
    v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Jul 2019 to Jul 15, 2020
    • Start date changed from estimate of May 25, 2018 to Dec 20, 2018
    • Study completion date: Oct 15, 2019 to Dec 15, 2020
    v3
  4. Start date: Oct 15, 2017 to May 25, 2018v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
XePOHCAS: Prospective, randomized, multicenter interventional trial in adult subjects with out-of-hospital cardiac arrest comparing treatment with standard-of-care post-cardiac arrest intensive care (which is targeted temperature management \[TTM\]) to xenon by inhalation plus standard-of-care post-cardiac arrest intensive care (including TTM).
Trial Details
NCT Number NCT03176186
Lead Sponsor Invero Pharma, Inc.
Conditions
(from sponsor)		 Post-Cardiac Arrest Syndrome
Related terms Out-of-Hospital Cardiac Arrest, Post-Cardiac Arrest Syndrome
Enrollment 1,436 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov